Walter Ageno1, Alexander S Gallus2, Ann Wittkowsky3, Mark Crowther4, Elaine M Hylek5, Gualtiero Palareti6. 1. University of Insubria, Varese, Italy. Electronic address: walter.ageno@uninsubria.it. 2. Flinders University, Adelaide, SA, Australia. 3. University of Washington, Seattle, WA, Canada. 4. McMaster University, St. Joseph's Hospital, Hamilton, ON, Canada. 5. Boston University School of Medicine, Boston, MA. 6. University Hospital S. Orsola-Malpighi, Bologna, Italy.
Abstract
BACKGROUND: The objective of this article is to summarize the published literature concerning the pharmacokinetics and pharmacodynamics of oral anticoagulant drugs that are currently available for clinical use and other aspects related to their management. METHODS: We carried out a standard review of published articles focusing on the laboratory and clinical characteristics of the vitamin K antagonists; the direct thrombin inhibitor, dabigatran etexilate; and the direct factor Xa inhibitor, rivaroxaban RESULTS: The antithrombotic effect of each oral anticoagulant drug, the interactions, and the monitoring of anticoagulation intensity are described in detail and discussed without providing specific recommendations. Moreover, we describe and discuss the clinical applications and optimal dosages of oral anticoagulant therapies, practical issues related to their initiation and monitoring, adverse events such as bleeding and other potential side effects, and available strategies for reversal. CONCLUSIONS: There is a large amount of evidence on laboratory and clinical characteristics of vitamin K antagonists. A growing body of evidence is becoming available on the first new oral anticoagulant drugs available for clinical use, dabigatran and rivaroxaban.
BACKGROUND: The objective of this article is to summarize the published literature concerning the pharmacokinetics and pharmacodynamics of oral anticoagulant drugs that are currently available for clinical use and other aspects related to their management. METHODS: We carried out a standard review of published articles focusing on the laboratory and clinical characteristics of the vitamin K antagonists; the direct thrombin inhibitor, dabigatran etexilate; and the direct factor Xa inhibitor, rivaroxaban RESULTS: The antithrombotic effect of each oral anticoagulant drug, the interactions, and the monitoring of anticoagulation intensity are described in detail and discussed without providing specific recommendations. Moreover, we describe and discuss the clinical applications and optimal dosages of oral anticoagulant therapies, practical issues related to their initiation and monitoring, adverse events such as bleeding and other potential side effects, and available strategies for reversal. CONCLUSIONS: There is a large amount of evidence on laboratory and clinical characteristics of vitamin K antagonists. A growing body of evidence is becoming available on the first new oral anticoagulant drugs available for clinical use, dabigatran and rivaroxaban.
Authors: M Kazama; S Suzuki; T Abe; C Tahara; C Shimazu; Y Akiyama; K Higashi; I Ishiguro; T Kimura; S Motoi Journal: Thromb Haemost Date: 1990-12-28 Impact factor: 5.249
Authors: F Mentré; F Pousset; E Comets; B Plaud; B Diquet; G Montalescot; A Ankri; A Mallet; P Lechat Journal: Clin Pharmacol Ther Date: 1998-01 Impact factor: 6.875
Authors: Stephen Couban; Michael Goodyear; Margot Burnell; Sean Dolan; Parveen Wasi; David Barnes; Darlene Macleod; Erica Burton; Pantelis Andreou; David R Anderson Journal: J Clin Oncol Date: 2005-03-14 Impact factor: 44.544
Authors: Dagmar Kubitza; Michael Becka; Barbara Voith; Michael Zuehlsdorf; Georg Wensing Journal: Clin Pharmacol Ther Date: 2005-10 Impact factor: 6.875
Authors: Daniel E Singer; Gregory W Albers; James E Dalen; Margaret C Fang; Alan S Go; Jonathan L Halperin; Gregory Y H Lip; Warren J Manning Journal: Chest Date: 2008-06 Impact factor: 9.410